Product Description
Visilizumab is a humanized antibody (antibodies are proteins that are normally made by the immune system to help defend the body from infections and other foreign substances) that is directed against T cells. Visilizumab selectively attacks problematic T cells and, in doing so, it may prevent them from causing inflammation. Visilizumab has also been observed to have a suppressive effect on the body's immune system (system in the body that reacts to foreign or occasionally one's own proteins). (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT00267722)
Mechanisms of Action: CD3 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colitis, Ulcerative
Phase 2: Graft vs Host Disease|Crohn Disease|Colitis, Ulcerative|Anal Fistula
Phase 1: Intestinal Cancer|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MCC-15033 | P2 |
Terminated |
Graft vs Host Disease |
2013-12-01 |
|
| 2005-003707-37 | P3 |
Completed |
Colitis, Ulcerative |
2012-05-25 |
|
| 2005-003481-42 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2011-04-10 |
|
| 2005-002063-87 | P3 |
Completed |
Colitis, Ulcerative |
2011-03-09 |